|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Louisiana State University Health Sciences Center Shreveport |
|---|---|
| Information provided by (Responsible Party): | James C. Patterson, II, MD. Ph, Louisiana State University Health Sciences Center Shreveport |
| ClinicalTrials.gov Identifier: | NCT00243451 |
Purpose
Our central hypothesis is that the early metabolic lesions of MCI can be reliably detected in individual subjects by objective analysis of [18]F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) brain images, earlier and more accurately than by subjective clinician rating.
| Condition | Intervention |
|---|---|
|
Mild Cognitive Impairment Mild Alzheimer's Disease |
Other: PET scan & fMRI |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Early Detection of Mild Cognitive Impairment in Individual Patients |
| Estimated Enrollment: | 34 |
| Study Start Date: | September 2003 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
Our goal with this proposal is a prospective, longitudinal study that will examine subjects over a three-year span to establish the presence of MCI, evaluate progression of disease, and determine the validity of this method in detecting early MCI. Specifically, we predict that by using our Cognitive Decline Index (CDI) method of objective examination of FDG PET brain images from patients diagnosed with MCI or mild AD, we can accurately discriminate very early abnormalities in cerebral metabolism, and that this research method can be validated and translated into a clinically useful tool for the early detection of MCI. Our long-range goals are the development of methods and tools that enable the detection of pathology in individual patients at risk for cognitive impairment.
Eligibility| Ages Eligible for Study: | 55 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Subjects must have a diagnosis of MCI or mild AD.
MCI Inclusion Criteria (patients):
MCI criteria met:
Not demented.
MCI Exclusion Criteria (patients):
Mild Alzheimer's Disease (AD) Inclusion criteria (patients):
Cognitive impairment manifested as memory problems, problems with language, difficulty carrying out motor activities, difficulty naming things, and/or problems planning or organizing, all of which impair function and are worsening over time.
Mild Alzheimer's Disease (AD) Exclusion Criteria:
MCI Inclusion criteria (controls)
MCI Exclusion criteria (controls)
MRI findings must be normal or unremarkable for the age of the patient. Examples of abnormal (exclusory) findings are occult lacunar infarct, arteriovenous malformation) Examples of non-exclusory findings include mild atrophy, mild to moderate periventricular white matter changes. Other MRI findings will be evaluated in consultation with coinvestigator neuroradiologists and clinical judgment will be used to determine if the subject can continue in the study.
Dropout criteria (all):
Subjects that begin the study and are not able to finish the study will be tracked. Ongoing criteria for termination from the study will include:
Contacts and Locations| United States, Louisiana | |
| Louisiana State University Health Sciences Center | |
| Shreveport, Louisiana, United States, 71103 | |
| Principal Investigator: | James Patterson, MD PhD | Louisiana State University Health Sciences Center |
More Information
| Responsible Party: | James C. Patterson, II, MD. Ph, Professor, Louisiana State University Health Sciences Center Shreveport |
| ClinicalTrials.gov Identifier: | NCT00243451 History of Changes |
| Other Study ID Numbers: | LSUHSC H04-049 |
| Study First Received: | September 13, 2005 |
| Last Updated: | September 2, 2011 |
| Health Authority: | United States: Institutional Review Board |
|
Alzheimer Disease Cognition Disorders Dementia Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Tauopathies Neurodegenerative Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders |